ישראל - עברית - Ministry of Health

novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).

ישראל - עברית - Ministry of Health

bayer israel ltd - aflibercept - תמיסה להזרקה לזגוגית העין - aflibercept 40 mg/ml - aflibercept

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - faricimab - תמיסה להזרקה - faricimab 120 mg/ml - faricimab

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - dexamethasone - שתל במתקן להחדרת תרופה - dexamethasone 0.7 mg - dexamethasone - dexamethasone - ozurdex is indicated for the treatment of adult patients with macular edema following either branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo).ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - ravulizumab - תרכיז להכנת תמיסה לאינפוזיה - ravulizumab 10 mg/ml - ravulizumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - palivizumab - תמיסה להזרקה - palivizumab 100 mg/ml - palivizumab

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - ravulizumab - תרכיז להכנת תמיסה לאינפוזיה - ravulizumab 100 mg/ml - ravulizumab

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.